| Women, n | Men, n |
---|---|---|
Total subjects | 1,390 | 1,158 |
CD diagnosed by histology before enrolment | 0 | 1 |
Abnormal composite TG2/DGP IgA/IgG, and TG2 IgA, or DGP IgA or IgG | 51 | 56 |
Findings diagnostic/supportive of untreated CD | Â | Â |
 Histological diagnosis: Intestinal villous atrophy, crypt hyperplasia, and IELs |  |  |
  Prompted by current study, 2010 | 6 | 4 |
  During standard medical care between 2004 and 2009 | 4 | 2 |
 Serological diagnosis: confirmation of multiple CD serological abnormalities |  |  |
  No supporting histological evidence obtained | 2 | 3 |
  Treating doctor excluded CD because patient was asymptomatic | 0 | 2 |
Findings equivocal for CD | Â | Â |
 Intestinal IELs +/− mild focal villous atrophy, or villous atrophy and crypt hyperplasia without IELs | 0 | 3 |
Findings excluded/were not supportive of CD | Â | Â |
 Normal intestinal histology without serological testing | 2 | 5 |
 Serological exclusion: CD serological abnormalities not replicated | 7 | 8 |
 Genotyping exclusion: testing for HLA DQ2.5/8/2.2 negative | 0 | 1 |
Follow-up not possible or not undertaken | Â | Â |
 Treating doctor did not investigate further as subject asymptomatic and/or performed blood tests unrelated to CD | 1 | 5 |
 Subject deceased and CD not diagnosed pre-mortem | 8 | 5 |
 Subject declined follow-up medical review | 16 | 11 |
 Subject could not be contacted; lost to follow-up | 5 | 7 |
CD cases estimated by serogenetic modeling, range | 12 to 26 | 12 to 16 |
Lower 95% CI for CD cases based on TG2+ EMA+ | 11 | 12 |